Tech • IA • Crypto
Who supplies Silicon Valley developers' drugs?
4/10TL;DR
A new wave of peptide-driven biohacking is sweeping Silicon Valley, blending promises of enhanced performance with early health incidents.
KEY POINTS
Explosion of the GLP-1 market
GLP-1-type anti-obesity drugs have sparked this trend, with a market estimated at $71 billion in the United States by 2025. These treatments now generate more revenue than the entire generative artificial intelligence sector, highlighting a massive shift in spending toward bodily optimization.
Shift toward non-medical uses
Beyond weight loss, users are experimenting with peptides to speed up healing, improve sleep, enhance social interactions, or extend their ability to work. In some tech circles, these substances are used to sustain up to 15 hours of continuous work, becoming a chemical equivalent of a stimulant.
An informal market dominated by China
Supply largely depends on Chinese vendors offering kits priced between $50 and $100. These products, often labeled “not for human use,” are purchased online, then reconstituted and injected without medical supervision. Searches related to Chinese peptides have increased 300-fold in one year, signaling rapid adoption.
Emerging culture and normalization
In San Francisco, events combining electronic music and biohacking now include on-site injection spaces. This staging helps normalize these experimental practices by embedding them in a tech culture that values performance and self-optimization.
Regulatory uncertainty and political signals
Most peptides in use are not approved for human use, except for GLP-1. However, Health Secretary Robert F. Kennedy Jr. has shown interest in these substances. The FDA has announced a review of their status, triggering immediate reactions in financial markets, with some stocks rising by 14%.
Early health incidents
Enthusiasm is already tempered by hospitalization cases. In Las Vegas, two women were admitted after injections at an anti-aging event. These incidents highlight the risks tied to lack of oversight, unreliable dosing, and absence of clinical validation.
CONCLUSION
Between biological innovation and risky experimentation, the rise of peptides marks a new frontier where the pursuit of performance extends beyond the digital realm directly into the human body.